Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the receipt of a RMB 172 million collaboration payment from Allist Pharmaceuticals Co., Ltd, a fellow Chinese pharmaceutical company. This payment includes a RMB 150 million upfront fee and a RMB 22.79 million R&D compensation.
The payment stems from a licensing agreement reached between the two companies in the latter half of last month, through which Allist secured rights to R&D, manufacturing, regulatory filing, and commercialization of Jacobio’s KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The deal is potentially worth RMB 850 million.
Glecirasib, a KRAS G12C inhibitor developed by Jacobio, is currently the subject of numerous clinical trials in China, the United States, and Europe for patients with advanced solid tumors with the KRAS G12C mutation. This includes combination therapy trials with the SHP2 inhibitor JAB-3312 in non-small cell lung cancer (NSCLC) and with cetuximab in colorectal cancer. The drug candidate’s potential in treating pancreatic cancer has been recognized with orphan drug designation in the United States and breakthrough therapy designation in China.
JAB-3312, a highly selective SHP2 allosteric inhibitor, is also being developed by Jacobio. The company is conducting clinical trials for JAB-3312 in monotherapy and in combination with glecirasib and other agents across China, the United States, and Europe. A Phase III study combining JAB-3312 with glecirasib for first-line KRAS G12C mutant NSCLC began last month.- Flcube.com
